
Gene editing: overhyped or unstoppable tide?
A new report from Evaluate Vantage looks at recent developments in gene editing and delivery.

In 2021 it paid to stay private when the chips were down
While biotech indices fell, 2021 saw private companies raise the largest amount of venture capital ever.

Biotech venture financing starts the year with a bang
With a record $7.1bn raised in the first quarter the cash available to private drug developers shows no signs of drying up.